GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart disease, Parkinson’s, sleep apnea and addiction.

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests.

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under anesthesia.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require hospitalization, new research shows. Numerous studies had already hinted that semaglutide might act on appetite centers in the brain to suppress the urge to drink,

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published Wednesday in JAMA Psychiatry said. The study examined about 228,000 people in Sweden who had alcohol use disorder and Type 2 diabetes.

Ozempic, a diabetes drug that has become a popular drug for weight loss, has another use that could help tens of millions of Americans, researchers say. In a study published in the journal JAMA Psychiatry,